Comparative In Vitro Activities of New Antibiotics for the Treatment of Skin Infections.
antimicrobial susceptibility
delafloxacin
skin infections
surveillance
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
08 04 2019
08 04 2019
Historique:
entrez:
9
4
2019
pubmed:
9
4
2019
medline:
1
7
2020
Statut:
ppublish
Résumé
Bacterial skin infections result in significant morbidity and have contributed to enhanced health-care resource utilization. The problem is heightened by emerging antimicrobial resistance. Multiple novel agents active against resistant pathogens that cause skin infections-including dalbavancin, tedizolid phosphate, oritavancin, and delafloxacin-have been approved over the past 5 years. Common features of these agents include gram-positive activity and favorable safety. Of these agents, delafloxacin is unique in being active against both gram-positive and gram-negative pathogens that cause skin infections, including those resistant to other antimicrobial agents. It is, therefore, an effective option for the treatment of skin infections.
Identifiants
pubmed: 30957168
pii: 5428809
doi: 10.1093/cid/ciz003
pmc: PMC6451995
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
S200-S205Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Clin Microbiol Infect. 2016 Apr;22 Suppl 2:S27-36
pubmed: 27125562
N Engl J Med. 2014 Jun 5;370(23):2180-90
pubmed: 24897083
J Antimicrob Chemother. 2017 Sep 1;72(9):2461-2468
pubmed: 28859442
Ther Clin Risk Manag. 2016 Feb 16;12:225-32
pubmed: 26937194
Int J Dermatol. 2016 Apr;55(4):e191-7
pubmed: 26892888
BMC Infect Dis. 2014 Jun 02;14:296
pubmed: 24889406
Future Microbiol. 2015;10(7):1111-23
pubmed: 26119479
Mayo Clin Proc. 2011 Dec;86(12):1230-43
pubmed: 22134942
Drug Des Devel Ther. 2016 Dec 22;11:65-82
pubmed: 28053508
Diagn Microbiol Infect Dis. 2017 Oct;89(2):151-157
pubmed: 28793964
Skin Therapy Lett. 2015 Sep-Oct;20(5):7-9
pubmed: 26382907
J Antimicrob Chemother. 2015 Feb;70(2):498-504
pubmed: 25362568
Diagn Microbiol Infect Dis. 2017 Feb;87(2):133-138
pubmed: 27866673
J Antimicrob Chemother. 2016 Mar;71(3):821-9
pubmed: 26679243
Lancet Infect Dis. 2014 Aug;14(8):696-705
pubmed: 24909499
N Engl J Med. 2014 Jun 5;370(23):2169-79
pubmed: 24897082
Clin Infect Dis. 1995 Jun;20 Suppl 2:S279-82
pubmed: 7548575
Ann Emerg Med. 2008 Mar;51(3):291-8
pubmed: 18222564
Antimicrob Agents Chemother. 2017 Mar 24;61(4):
pubmed: 28167542
Diagn Microbiol Infect Dis. 2007 Jan;57(1):7-13
pubmed: 17059876
Arch Intern Med. 2008 Jul 28;168(14):1585-91
pubmed: 18663172
Antimicrob Agents Chemother. 2017 Aug 24;61(9):
pubmed: 28630189
Antimicrob Agents Chemother. 2009 Mar;53(3):1260-3
pubmed: 19124664
Antimicrob Agents Chemother. 2011 Feb;55(2):649-58
pubmed: 21135179
J Antimicrob Chemother. 2016 Jan;71(1):276-8
pubmed: 26451012
Int J Infect Dis. 2013 Feb;17(2):e115-9
pubmed: 23092752
Clin Microbiol Infect. 2017 Oct;23(10):697-703
pubmed: 28642145
Diagn Microbiol Infect Dis. 2013 May;76(1):122-3
pubmed: 23433533
JAMA. 2013 Feb 13;309(6):559-69
pubmed: 23403680
BMC Infect Dis. 2013 May 30;13:252
pubmed: 23721377
Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S54-S62
pubmed: 30895215
Can Fam Physician. 2017 Jul;63(7):512-520
pubmed: 28701438
J Antimicrob Chemother. 2017 Dec 01;72(12):3471-3480
pubmed: 29029278
Infect Dis Ther. 2016 Mar;5(1):1-15
pubmed: 26831328
Diagn Microbiol Infect Dis. 2013 Mar;75(3):304-7
pubmed: 23357293
PLoS One. 2015 Nov 24;10(11):e0143276
pubmed: 26599005